| Angiochem Validates its EPiC Technology via Rare Disease Deal with GSK |
Abstract
|
|
Heather Cartwright |
|
| Shire Collaborates with arGEN-X to Discover and Develop Antibody Products for Rare Diseases |
Abstract
|
|
Heather Cartwright |
|
| Mersana Therapeutics Raises Profile with Antibody-Drug Conjugate Collaboration with Endo |
Abstract
|
|
Heather Cartwright |
|
| Medicago and Mitsubishi Tanabe Pharma Form Vaccines Alliance |
Abstract
|
|
Heather Cartwright |
|
| Galapagos Lands US$1.35 B Deal with Abbott for Phase II JAK Inhibitor |
Abstract
|
|
Heather Cartwright |
|
| Avanir Licenses Concert’s Deuterium-Modified Dextromethorphan Products in Potential US$200 M Deal |
Abstract
|
|
Heather Cartwright |
|
| Dainippon Sumitomo Pharma Expands its Oncology Presence with Boston Biomedical Acquisition |
Abstract
|
|
Heather Cartwright |
|
| Shire Bolsters its Haematology Business with US$325 M FerroKin BioSciences Acquisition |
Abstract
|
|
Heather Cartwright |
|
| GSK Finds a Buyer in Omega Pharma for its Non-Core OTC Brands in Europe |
Abstract
|
|
Heather Cartwright |
|
| Sanofi Augments its Biosurgery Unit with Pluromed Acquisition |
Abstract
|
|
Heather Cartwright |
|
| NicOx Targets Ophthalmology with Altacor Buyout Option |
Abstract
|
|
Heather Cartwright |
|
| Daiichi Sankyo and GSK to Establish Vaccines Joint Venture in Japan |
Abstract
|
|
Heather Cartwright |
|
| Actelion Gains Rights to Auxilium’s Xiaflex® in Canada, Australia, Brazil and Mexico |
Abstract
|
|
Heather Cartwright |
|
| Novartis’ Alcon Gains ex-US Rights to ThromboGenics’ Ocriplasmin |
Abstract
|
|
Heather Cartwright |
|
